Cabaletta Bio, Inc. (NASDAQ: CABA) has received a consensus “Buy” recommendation from eight research firms, with an average price target of $22.71. Recent analyst ratings include Wells Fargo downgrading the stock to “equal weight” with a target of $6, while HC Wainwright maintained a “buy” with a $25 target. Institutional investors have increased their holdings significantly, with Two Sigma Advisers boosting their stake by 195.8%. Currently, CABA stock is trading at $1.85, down 1.6%, with a market cap of $90.42 million. The company focuses on engineered T cell therapies for autoimmune diseases, with its lead candidate, CABA-201, in clinical trials.